Holen Sie sich die Stockscreener-App
6.88
3.30%
0.22
Handel nachbörslich:
6.96
0.08
+1.16%
Schlusskurs vom Vortag:
$6.66
Offen:
$6.67
24-Stunden-Volumen:
2.81M
Relative Volume:
1.18
Marktkapitalisierung:
$686.10M
Einnahmen:
$58.36M
Nettoeinkommen (Verlust:
$-25.72M
KGV:
-18.90
EPS:
-0.3641
Netto-Cashflow:
$-24.91M
1W Leistung:
+15.24%
1M Leistung:
+36.24%
6M Leistung:
+173.02%
1J Leistung:
+42.15%
1-Tages-Spanne:
$6.51
$6.97
1-Wochen-Bereich:
$5.91
$6.97
52-Wochen-Spanne:
$2.12
$6.97
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Firmenname
Aquestive Therapeutics Inc
Sektor
Telefon
908-941-1900
Adresse
30 TECHNOLOGY DRIVE, WARREN, NJ
Vergleichen Sie AQST mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
6.88 | 791.17M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
143.46 | 63.05B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.80 | 43.33B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.17 | 40.43B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.11 | 22.97B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
433.61 | 19.90B | 3.08B | 1.24B | 1.07B | 25.61 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-10 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-28 | Eingeleitet | Raymond James | Outperform |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2019-04-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-03 | Eingeleitet | Lake Street | Buy |
| 2018-08-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2018-08-20 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aquestive Therapeutics Inc Aktie (AQST) Neueste Nachrichten
Why Aquestive Therapeutics Inc. stock could outperform in 2025Portfolio Return Report & Real-Time Buy Zone Alerts - newser.com
Is Aquestive Therapeutics Inc. stock ready for a breakout2025 Dividend Review & Scalable Portfolio Growth Ideas - newser.com
Volatility clustering patterns for Aquestive Therapeutics Inc.July 2025 Final Week & Real-Time Volume Spike Alerts - newser.com
Can trapped investors hope for a rebound in Aquestive Therapeutics Inc.Market Activity Recap & Daily Technical Forecast Reports - newser.com
Top chart patterns to watch in Aquestive Therapeutics Inc.2025 Historical Comparison & Expert Verified Stock Movement Alerts - newser.com
Is Aquestive Therapeutics Inc. reversing from oversold territoryJuly 2025 Market Mood & Safe Entry Momentum Tips - newser.com
Aquestive Therapeutics Stock: A Measured Bet (NASDAQ:AQST) - Seeking Alpha
Aquestive Therapeutics (NASDAQ:AQST) Hits New 12-Month HighShould You Buy? - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Advances Pharma Delivery - Kalkine Media
Aquestive Therapeutics (NASDAQ:AQST) Shares Up 7%Still a Buy? - MarketBeat
Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains? - Yahoo Finance
Watching the Narrative for Aquestive Therapeutics Shift After Key Anaphylm Milestones - Yahoo Finance
How to build a dashboard for Aquestive Therapeutics Inc. stockStock Surge & Momentum Based Trading Signals - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Aquestive Therapeutics (NASDAQ:AQST) - MarketBeat
JMP Securities Maintains Aquestive Therapeutics (AQST) Market Outperform Recommendation - Nasdaq
What high frequency data says about Aquestive Therapeutics Inc.July 2025 Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™ - GlobeNewswire
Aquestive Therapeutics Shares Rise After Obtaining 2 New US Patents for Anaphylm Sublingual Film - MarketScreener
Aquestive Therapeutics Obtains 2 New US Patents for Anaphylm Sublingual Film - MarketScreener
Aquestive receives two new patents for oral anaphylaxis treatment By Investing.com - Investing.com Australia
Aquestive receives two new patents for oral anaphylaxis treatment - Investing.com India
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™ - GlobeNewswire Inc.
Signal strength of Aquestive Therapeutics Inc. stock in tech scanners2025 Technical Patterns & Safe Capital Growth Trade Ideas - newser.com
Why Aquestive Therapeutics Inc. stock is seen as undervaluedWeekly Profit Summary & Community Verified Watchlist Alerts - newser.com
Custom watchlist performance reports with Aquestive Therapeutics Inc.2025 Dividend Review & Free Expert Verified Stock Movement Alerts - newser.com
Statistical indicators supporting Aquestive Therapeutics Inc.’s strengthTrade Analysis Summary & Comprehensive Market Scan Insights - newser.com
Advanced analytics toolkit walkthrough for Aquestive Therapeutics Inc.Portfolio Profit Report & AI Forecast for Swing Trade Picks - newser.com
Aquestive Therapeutics Advances Anaphylm Clinical Development - TipRanks
Aquestive Therapeutics SVP sells $63,000 in shares By Investing.com - Investing.com Nigeria
Aquestive Therapeutics CEO Barber sells $551k in shares By Investing.com - Investing.com Canada
Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $550,798.29 in Stock - MarketBeat
Peter Boyd Sells 10,000 Shares of Aquestive Therapeutics (NASDAQ:AQST) Stock - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Trading Down 5.3% After Insider Selling - MarketBeat
Aquestive Therapeutics SVP sells $63,000 in shares - Investing.com
Aquestive Therapeutics Hits New 52-Week High of $6.00, Up 105.43% - Markets Mojo
Finanzdaten der Aquestive Therapeutics Inc-Aktie (AQST)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aquestive Therapeutics Inc-Aktie (AQST) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Boyd Peter E. | See Remarks |
Sep 26 '25 |
Sale |
6.30 |
10,000 |
63,000 |
278,323 |
0.90%
2.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):